Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024 (Sutro Biopharma Press Release) - Dec 14, 2023 - "Sutro Biopharma, Inc...announced that it will host an investor webcast to highlight the broad opportunity for its foundational ADC program, Luveltamab tazevibulin (luvelta), a novel folate receptor-α (FolRα) targeting ADC which has now shown clinical activity in three different tumor types to date. The live webcast will be held on Thursday, January 4, 2024, starting at 1:30 p.m. PT / 4:30 p.m. ET featuring presentations by members of Sutro's senior management team and external key opinion leaders in oncology; and concluding with a Q&A session....The Company is currently enrolling patients in Part I of REFRaME-O1, a Phase 2/3 registration-directed study for patients with platinum-resistant ovarian cancer (PROC). Sutro will highlight the significant opportunity for luvelta in ovarian cancer, as well as the potential for luvelta in a range of additional FolRα expressing cancers, including endometrial cancer, CBFA2T3::GLIS2..."
Clinical • Trial status • Acute Myelogenous Leukemia • Endometrial Cancer • Gynecologic Cancers • Hematological Malignancies • Leukemia • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Uterine Cancer
|